TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06054698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection , QW，36 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 injection Placebo
Description: HRS9531 injection Placebo，QW，36 weeks
Study: NCT06366490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Innocell Autologous Cellular Immunotherapy
Description: Innocell Autologous Cellular Immunotherapy
Study: NCT05292521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive QOL fact sheet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05525455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-816
Description: TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-816
Description: TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A PD-1 inhibitor
Description: Programmed death receptor-1 (PD 1)-blocking antibody
Study: NCT05784194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention for correct discharge medication list
Description: As above
Study: NCT04911166

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab and Interleukin-12 Gene Therapy
Description: To determine the safety and tolerability of the atezolizumab and ADV/IL-12 gene therapy combination in patients with metastatic NSCLC who have disease progression after a prior line of either single agent immunotherapy or a regimen of chemoimmunotherapy.
Study: NCT04815993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 delayed release capsule
Description: SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 delayed release capsule
Description: SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 delayed release capsule
Description: SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 delayed release capsule
Description: SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
Study: NCT06396689

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: The capsule contains Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, and Bifidobacterium bifidum R0071 (3 billion bacteria per capsule), as well as zinc oxide, potato starch fructooligosaccharides, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The capsule contains zinc oxide, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The capsule contains zinc oxide, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
Study: NCT06403553

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Calprotectin
Description: Fecal Calprotectin measurement on days 1and 3

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Calprotectin
Description: Fecal Calprotectin measurement on days 1and 3
Study: NCT05336734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: see group description
Study: NCT05223179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CODA-VAX H1N1
Description: Intramuscular Live Attenuated Influenza H1N1 Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flucelvax Quad
Description: Licensed Seasonal Injectable Influenza Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT05993429

Intervention type: DIAGNOSTIC_TEST
Intervention: The sampling method selected in patients with suspected hilar cholangiocarcinoma
Description: The appropriate sampling approach was selected as EUS-FNA/B or ERCP with or without POCS-TB based on experts' overall evaluation. This study will compare the histopathological diagnosis of the selected sampling method with the final diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: The sampling method selected in patients with suspected hilar cholangiocarcinoma
Description: The appropriate sampling approach was selected as EUS-FNA/B or ERCP with or without POCS-TB based on experts' overall evaluation. This study will compare the histopathological diagnosis of the selected sampling method with the final diagnosis.
Study: NCT04763759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRL1068, a human monoclonal antibody
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRL1068, a human monoclonal antibody
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRL1068, a human monoclonal antibody
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
Study: NCT05788419

Intervention type: DIAGNOSTIC_TEST
Intervention: sonography
Description: imaging method, functional test of hip joint

Intervention type: DIAGNOSTIC_TEST
Intervention: sonography
Description: imaging method, functional test of hip joint
Study: NCT04774588

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.
Description: 1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time

Intervention type: OTHER
Group type: OTHER
Intervention: VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.
Description: 1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
Study: NCT05203211

Intervention type: PROCEDURE
Intervention: Testicular sperm extraction (TESE)
Description: During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
Study: NCT05594498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataXRT
Description: StrataXRT is a silicone-based film-forming topical gel that may help in reducing radiation dermatitis.
Study: NCT05236452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training for traditional and modern care providers
Description: The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training for traditional and modern care providers
Description: The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
Study: NCT06024239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-932
Description: Capsule; oral
Study: NCT05947695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative and Survivorship Care Model
Description: The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Palliative and Survivorship Care Model
Description: The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
Study: NCT04694794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Brochure
Description: Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
Study: NCT05375786

Intervention type: BIOLOGICAL
Intervention: Vaccination completion status
Description: the relation between vaccination completion status and the target population
Study: NCT06024239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-932
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-932
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-932
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-932
Description: Capsule; oral
Study: NCT04923737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
Study: NCT05061771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nomacopan (rVA576)
Description: Nomacopan an inhibitor of complement C5 and LTB4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05846945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Threshold inspiratory muscle trainer device
Description: The threshold inspiratory muscle trainer (IMT) device offers resistance to respiration through the spring-loaded valve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjusting mechanical ventilator trigger sensitivity
Description: modifying the mechanical ventilator trigger sensitivity so that patients can only initiate inspiratory flow by producing more negative intrathoracic pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy
Description: Conventional chest physiotherapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Chest physiotherapy
Description: Conventional chest physiotherapy
Study: NCT04707001

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization based on ultrasound
Description: Bladder volume ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization based on evaluation of symptoms
Description: Ask for symptoms: Need to urinate, lower abdominal pain
Study: NCT04527094

Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of postoperative respiratory failure using a machine learning
Description: The performance of a machine learning model to predict postoperative respiratory failure after general anesthesia within postoperative day 7 was tested prospectively.
Study: NCT04163042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week videoconferencing behavioural support intervention to promote physical activity behaviour
Description: Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
Study: NCT05797727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeChamps Platform HCP
Description: Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeChamps Platform
Description: Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires
Study: NCT05243121

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: undergoing enhanced MRI
Study: NCT05846945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy
Description: Conventional chest physiotherapy
Study: NCT06270498

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrosomial iron
Description: Sucrosomial iron with the addition at a fixed dose of vitamin C to promote iron absorption (SiderAL® Forte) will be administered orally once a day for 12 weeks.~The dose regimen for all participants will be calculated according to the haemoglobin (Hb) levels at baseline evaluation and to patient's body weight as follows:~Hb 14-15 g/dL: 1 tablet once a day, corresponding to 30 mg/daily, for 12 weeks; Hb 10-13.9 g/dL: 2 tablets once a day, corresponding to 60 mg/daily, for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be identical in shape, form and color of SI pills; they will contain the same components of SiderAL Forte® except for sucrosomial iron and vitamin D.~Placebo will be administered orally once a day for 3 months according to the same dose scheme in the intervention arm.
Study: NCT04885361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoVepiT (OSE13E)
Description: Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoVepiT (OSE13E)
Description: Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
Study: NCT04733118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab and Pertuzumab (FDC SC) and T-DM1
Description: Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~* Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~* Cohort B: T-DM1 ± ET for 10 cycles~* Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1.
Study: NCT05447520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional DMARDs
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional DMARDs
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
Study: NCT06391008

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Targeting primary lung lesions and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy was performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evoximab
Description: Evoximab (20mg/kg, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (500mg/m2, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Albumin Paclitaxel 260 mg/m2, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC5, Q3W)
Study: NCT05139719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585 dose A
Description: taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC585 dose A
Description: taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585 dose B
Description: taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taking Placebo orally once daily, up to 24 weeks in main stage
Study: NCT05103501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）
Description: immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP
Study: NCT05561634

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Radiotherapy
Description: Irradiation of the tumoral bed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Irradiation of the tumoral bed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation
Description: Patients will be followed up in consultation every 3 months.
Study: NCT04473924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Body surface area-based dosing of mycophenolate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Standard (fixed) dosing of mycophenolate
Study: NCT05561634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,